Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection

A massive vaccination campaign against the global COVID-19 pandemic caused by SARS-CoV-2 virus began worldwide in January 2021. However, studies continue to investigate the most effective and safe drug therapies to manage the various stages of viral infection. It is critical in the therapeutic manag...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitiello, Antonio, Ferrara, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527301/
https://www.ncbi.nlm.nih.gov/pubmed/34669002
http://dx.doi.org/10.1007/s00210-021-02169-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527301/
https://www.ncbi.nlm.nih.gov/pubmed/34669002
http://dx.doi.org/10.1007/s00210-021-02169-0

Ejemplares similares